MINI-FUTURE LONG - ELI LILLY & CO | Market Closed - Swiss Exchange 08:50:00 03/06/2024 pm IST | ||
| 2.72 CHF | +3.42% |
|
| Current month | +3.42% | ||
| 1 month | +43.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 2.72 | +3.42% |
| 31/24/31 | 2.63 | -0.38% |
| 30/24/30 | 2.64 | +0.76% |
| 29/24/29 | 2.62 | -0.38% |
| 27/24/27 | 2.63 | +0.38% |
Delayed Quote Swiss Exchange
Last update June 03, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYCLU | |
| ISIN | CH1292908634 |
| Date issued | 01/09/2023 |
| Strike | 528.1 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.51 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.72 CHF |
|---|---|
| Lowest since issue | 0.24 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.37% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.3
USD
Average target price
852.5
USD
Spread / Average Target
+2.56%
- Stock Market
- Certificates
- LLYCLU Certificat
